Taking into account that SARS-CoV-2 variants might emerge, which may acquire resistance to currently available monoclonal antibodies, COVID-19 CP should be considered as first-line therapy, which is efficient when applied early with adequate neutralizing antibody activity present. This evidence concerns the gene CP and COVID-19.